Table 2.
AUC of clinicopathologic characteristics for recurrence status∗1.
| Variable | AUC | High risk | Low risk | Sensitivity | Specificity |
|---|---|---|---|---|---|
| Tumor size (cm) | 0.679 | ≥2.4 cm | <2.4 cm | 0.677 | 0.682 |
| Stage | 0.671 | II, III | I | 0.941 | 0.400 |
| ER | 0.651 | Negative | Positive | 0.588 | 0.714 |
| HT | 0.645 | No | Yes | 0.618 | 0.673 |
| LN metastasis | 0.633 | Positive | Negative | 0.588 | 0.677 |
| Age | 0.625 | ≥52 yrs | <52 yrs | 0.677 | 0.573 |
| PR | 0.619 | negative | positive | 0.647 | 0.591 |
| MRE11 positive cells | 0.592 | >50% | ≤50% | 0.853 | 0.332 |
| BMI | 0.566 | ≥24 | <24 | 0.559 | 0.573 |
| HER2 status | 0.535 | Negative | Positive | 0.706 | 0.364 |
| Grade | 0.524 | 3 | 1, 2 | 0.294 | 0.755 |
| CT | 0.505 | No | Yes | 0.147 | 0.864 |
| RT | 0.396 | No | Yes | 0.206 | 0.586 |
∗1Data for high/low risks of breast cancer recurrence were retrieved from our previous study [9]. AUC: area under receiver operating characteristic; ER: estrogen receptor; HT: hormone therapy; LN: lymph node; PR: progesterone receptor; MRE11: meiotic recombination 11; BMI: body mass index; HER2: human epidermal growth factor receptor 2; CT: chemotherapy; RT: radiotherapy.